biodoc, great post, thanks. As far as the Bril dosing, could that be the point that most people have a good response with fewest side effects? Is it possible that there's a "tipping point" with the slightly higher dose that greatly increase the side effects, and they don't want to take a chance on non-approval because of that? Do you think a second dose several days later for people who don't seem to be responding would be a possible dosing schedule for infections that weren't responding to the single dose?

I think your Bril-OM analysis of Leo talking about other inflammatory conditions now is spot on -- he's hinting at efficacy.

Is it possible that Kevetrin "turns on" the gene and the effect lasts much longer than the half-life of the drug even with K no longer being infused, but then wears off? OT: As far as the pump infusion model, which sounds great, our friends over at the CRMD board at investors' village think that CRMD's disinfectant solution will solve a big problem with infections at ports -- are you familiar with CRMD's stuff? I have an EXTREMELY small position in CRMD at about break-even now. Haven't researched them enough to feel comfortable with a big position.